1462-8902 < 1463-1326 < 1464-3391

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f Mesh.f MeshFr.f KwdFr.f

List of bibliographic references indexed by 1463-1326

Number of relevant bibliographic references: 17.

Ident.	Authors (with country if any)	Title
000255 (2019)	Gian Paolo Fadini [Italie] ; Veronica Sciannameo [Italie] ; Ivano Franzetti [Italie] ; Daniele Bottigliengo [Italie] ; Paola D'Angelo [Italie] ; Carmela Vinci [Italie] ; Paola Berchialla [Italie] ; Salvatore Arena [Italie] ; Raffaella Buzzetti [Italie] ; Angelo Avogaro [Italie]	Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.
000851 (2018)	David Russell-Jones [Royaume-Uni] ; Frans Pouwer [Danemark] ; Kamlesh Khunti [Royaume-Uni]	Identification of barriers to insulin therapy and approaches to overcoming them.
000909 (2018)	Veronika Voronova [Russie] ; Kirill Zhudenkov [Russie] ; Robert C. Penland [États-Unis] ; David W. Boulton [États-Unis] ; Gabriel Helmlinger [États-Unis] ; Kirill Peskov [Russie]	Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology model.
000936 (2018)	Milton Packer [États-Unis]	Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
000994 (2018)	Dong-Mei Liu [République populaire de Chine] ; Ioanna Mosialou [États-Unis] ; Jian-Min Liu [République populaire de Chine]	Bone: Another potential target to treat, prevent and predict diabetes.
000A09 (2018)	Hiddo J L. Heerspink [Pays-Bas] ; Dennis L. Andress [États-Unis] ; George Bakris [États-Unis] ; John J. Brennan [États-Unis] ; Ricardo Correa-Rotter [Mexique] ; Fan Fan Hou [République populaire de Chine] ; Dalane W. Kitzman [États-Unis] ; Donald Kohan [États-Unis] ; Hirofumi Makino [Japon] ; John Mcmurray [Royaume-Uni] ; Vlado Perkovic [Australie] ; Sheldon Tobe [Canada] ; Melissa Wigderson [États-Unis] ; Tingting Yi [États-Unis] ; Hans-Henrik Parving [Danemark] ; Dick De Zeeuw [Pays-Bas]	Baseline characteristics and enrichment results from the SONAR trial.
000C18 (2017)	Karin Stadlbauer [Autriche] ; Barbara Brunmair [Autriche] ; Zsuzsanna Lehner [Autriche] ; Immanuel Adorjan [Autriche] ; Thomas Scherer [Autriche] ; Anton Luger [Autriche] ; Leonhardt Bauer [Autriche] ; Clemens Fürnsinn [Autriche]	Preclinical characterization of 55P0251, a novel compound that amplifies glucose-stimulated insulin secretion and counteracts hyperglycaemia in rodents.
000C31 (2017)	Jean-Claude Henquin [Belgique] ; Denis Dufrane [Belgique] ; Valery Gmyr [France] ; Julie Kerr-Conte [France] ; Myriam Nenquin [Belgique]	Pharmacological approach to understanding the control of insulin secretion in human islets.
000D62 (2017)	Martin L. K Rhus [Danemark] ; Andreas Br Nden [Danemark] ; David P. Sonne [Danemark] ; Tina Vilsb Ll [Danemark] ; Fillip K. Knop [Danemark]	Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: A review.
001156 (2016)	H A Dowlat [Allemagne] ; M K Kuhlmann [Allemagne] ; H. Khatami [États-Unis] ; F J Ampudia-Blasco [Espagne]	Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications.
001A80 (2014)	R. Herring [Royaume-Uni] ; R H Jones ; D L Russell-Jones	Hepatoselectivity and the evolution of insulin.
001B60 (2014)	Y. Liu [République populaire de Chine] ; T. Hong	Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
001E80 (2013)	N. Irwin [Royaume-Uni] ; K. Hunter ; I A Montgomery ; P R Flatt	Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
002470 (2011)	T. Hata [Italie] ; Y. Mera ; H. Tadaki ; Y. Kuroki ; T. Kawai ; T. Ohta ; M. Kakutani	JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses high fat diet-induced obesity and glucose intolerance in Sprague-Dawley rats.
002C21 (2008)	G. Garcia-Soria [Mexique] ; G. Gonzalez-Galvez ; G M Argoud ; M. Gerstman ; T W Littlejohn ; S L Schwartz ; A-M O'Farrell ; X. Li ; J M Cherrington ; C. Bennett ; H-P Guler	The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus.
002D53 (2008)	J. Chen [États-Unis] ; E. Alemao ; D. Yin ; J. Cook	Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications.
002D63 (2008)	I. Aberle [Suisse] ; D. Zimprich ; B. Bach-Kliegel ; C. Fischer ; M. Gorny ; A. Kliegel ; K. Langer ; M. Kliegel	Continuous subcutaneous insulin infusion leads to immediate, stable and long-term changes in metabolic control.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/BiopestPeptidV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/ISSN.i -k "1463-1326" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/ISSN.i  \
                -Sk "1463-1326" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    BiopestPeptidV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    ISSN.i
   |clé=    1463-1326
}}

---

This area was generated with Dilib version V0.6.38. Data generation: Thu Nov 19 19:22:35 2020. Site generation: Thu Nov 19 19:33:26 2020